Data from three phase III trials of LY 2605541 (basal insulin peglispro) show benefit in type 2 diabetes

Eli Lilly and Company's LY 2605541 (basal insulin peglispro) consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with type 2 diabetes compared to insulin glargine across three Phase III trials. The trials compared LY 2605541 and insulin glargine in three common type 2 patient populations: those not previously using insulin (IMAGINE-2), those using basal insulin with mealtime insulin (IMAGINE-4) and those currently using a basal insulin (IMAGINE-5).

Additional data from IMAGINE-2, IMAGINE-4 and IMAGINE-5 showed that more patients taking LY 2605541 consistently met the ADA's recommended HbA1c target of less than 7 percent. A greater percentage of LY 2605541-treated patients also reported less nocturnal hypoglycemia compared to those on insulin glargine. Rates of total and severe hypoglycemia did not differ significantly between treatment groups. Patients taking LY 2605541 experienced less weight gain than patients taking insulin glargine in IMAGINE-2 and IMAGINE-4.

In all three clinical trials, patients taking LY 2605541 had an increase in the liver enzyme ALT (alanine aminotransferase), and triglyceride levels were higher than in patients treated with insulin glargine. Liver fat content was higher after treatment with LY 2605541 compared to insulin glargine in subsets of patients studied from IMAGINE-2 and IMAGINE-5. The results were presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.